Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE

NCT01702038 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Lupus Erythematosus, Systemic

Interventions

DRUG: Rituximab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)